Events

E.g., 10/07/2025

  • 12th Annual Pediatric Specialty Updates for the General Practitioner

    Saturday, December 6, 2025 to Sunday, December 7, 2025
    All day
    Online Event
    • College of Physicians and Surgeons
    This program will be of interest to general pediatricians who are interested in expanding their knowledge in a variety of subspecialty areas with new or updated guidelines or practice parameters that impact primary pediatric care. In particular, healthcare providers who do not feel comfortable in recognizing or managing patients with the above conditions will benefit from this conference. The subspecialty topics covered in the conference deal with conditions that generally involve a team approach for patient care, including the primary care physician and the subspecialist. The conference will provide the primary care physician with practical information that will help them to become more knowledgeable in identifying, understanding, and co-managing a variety of complex conditions along with the subspecialist. The conference will also provide an opportunity for the primary care physicians to ask questions directly to the participating subspecialists to further enhance their understanding of the conditions discussed. The combination of didactic and interactive elements will promote a more effective learning experience.

  • HICCC Seminar Series - Scientific Seminar

    Wednesday, December 10, 2025
    4:00 PM to 5:00 PM
    Herbert Irving Comprehensive Cancer Center, 1130 St. Nicholas Ave., New York, NY 10032 1st Floor Auditorium
    • College of Physicians and Surgeons
    Michel Sadelain, MD, PhD Herbert and Florence Irving Professor of Medicine  Department of Medicine, Hematology & Oncology Program: Precision Oncology and Systems Biology (POSB) Title: Antigen sensitivity, logic gating and persistence of CAR T cells Description: As a pioneer in CAR-T therapy, Dr. Sadelain has brought revolutionary changes to cancer treatment: successfully using retroviral vectors to genetically engineer T cells; being the first to introduce the CD28 co-stimulatory domain into the CAR structure, designing the "second-generation" CAR, establishing the feasibility of CAR-T cell therapy; being the first to prove that the CD19 molecule found on the surface of blood cells can serve as an effective target for CAR-T cells, advancing clinical trials for CAR-T cell therapy, achieving significant therapeutic effects. mammals. Dr. Sadelain continues to deepen the understanding of CAR-T cell therapy, including improving the antigen sensitivity of CAR-T cells, developing new strategies to regulate CAR-T activation with logic gating, and using CRISPR technology to enhance the potency, durability, and safety of CAR-T cells. These efforts aim to surmount resistance mechanisms conferred by tumor cells and their microenvironment, thereby broadening the applicability of CAR-T cell therapy across a spectrum of cancer types. The event is hybrid.  Join Zoom Meeting https://columbiacuimc.zoom.us/j/98062087107?pwd=ODN1TFwbtR23dO0Pk7Bq73td7fG91L.1 Meeting ID: 980 6208 7107 Passcode: 267022

Pages